WNK1 and neoplasm: Despite its relatively low potency and short half-life, Compound 12 showed promising anti-tumour effectiveness and low side effects, indicating a great potential for developing or optimising WNK1 inhibitory compounds with enhanced bioavailability, stability, and potency to treat patients with AML and other cancers dependent on this pathway.